David M Thomas1, Keith M Skubitz. 1. Departments of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. david.thomas@petermac.org
Abstract
PURPOSE OF REVIEW: Giant cell tumour of bone (GCT) is the most common benign bone tumour and afflicts a young population. Treatment options for patients with unresectable disease have remained fairly static for the past three decades. RECENT FINDINGS: Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL), in the genesis of GCT. The development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT. This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated. Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor. SUMMARY: Denosumab presents a new treatment option for patients with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.
PURPOSE OF REVIEW: Giant cell tumour of bone (GCT) is the most common benign bone tumour and afflicts a young population. Treatment options for patients with unresectable disease have remained fairly static for the past three decades. RECENT FINDINGS: Recent discoveries have identified a key role for the osteoclast differentiation factor, receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL), in the genesis of GCT. The development of the fully human monoclonal antibody to RANKL, denosumab, has led to a clinical trial in unresectable GCT. This study demonstrated an 86% response rate, with comparable evidence of clinical benefit, and was well tolerated. Other pathways that may present targets for therapy include the hypoxia-angiogenesis axis and the colony stimulating factor 1 receptor. SUMMARY:Denosumab presents a new treatment option for patients with previously untreatable GCT. The eventual role of denosumab and other targeted agents in the treatment of GCT and related disorders is currently the subject of active study.
Authors: Pietro Ruggieri; Andreas F Mavrogenis; Giuseppe Ussia; Andrea Angelini; Panayiotis J Papagelopoulos; Mario Mercuri Journal: Clin Orthop Relat Res Date: 2010-11 Impact factor: 4.176
Authors: Nicole A Karras; Lynda E Polgreen; Christian Ogilvie; J Carlos Manivel; Keith M Skubitz; Emily Lipsitz Journal: J Clin Oncol Date: 2013-03-18 Impact factor: 44.544
Authors: Noah Federman; Earl W Brien; Vivek Narasimhan; Sarah M Dry; Monish Sodhi; Sant P Chawla Journal: Paediatr Drugs Date: 2014-02 Impact factor: 3.022
Authors: Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis Journal: Diagn Pathol Date: 2010-09-22 Impact factor: 2.644